InnoCare's Next-Generation TRK Inhibitor Zurletrectinib Receives NMPA Approval in China for NTRK Fusion-Positive Solid Tumors
Key Insights
InnoCare's zurletrectinib (ICP-723) has received approval from China's NMPA for treating adult and adolescent patients with NTRK fusion-positive solid tumors (search), marking the company's first approved solid tumor therapy.
The registrational trial demonstrated exceptional efficacy with an 89.1% objective response rate, 96.4% disease control rate, and 24-month progression-free survival and overall survival rates of 77.4% and 90.8% respectively.
The next-generation TRK (search) inhibitor showed superior performance compared to first-generation agents, with 100% response rates in thyroid cancer (search) patients and strong brain penetration activity for patients with brain metastases (search).
InnoCare Pharma (search) announced that its next-generation TRK (search) inhibitor, zurletrectinib (ICP-723), has received approval from China's National Medical Products Administration (NMPA) for treating adult and adolescent patients aged 12 years and older with solid tumors harboring NTRK (search) gene fusions. This marks InnoCare's third innovative drug approved for marketing and its first solid tumor therapy to receive regulatory approval.
Exceptional Clinical Efficacy Demonstrated
The registrational clinical trial for patients with NTRK fusion-positive solid tumors (search) revealed outstanding efficacy results. Zurletrectinib achieved an objective response rate (ORR) of 89.1% and a disease control rate (DCR) of 96.4%. The 24-month progression-free survival (PFS) and overall survival (OS) rates reached 77.4% and 90.8% respectively, demonstrating sustained clinical benefit.
The drug showed particularly impressive results across different tumor types. In thyroid cancer (search) patients, the ORR reached 100%, with patients maintaining therapy for two years with sustained responses. For soft tissue sarcoma (search) patients, zurletrectinib demonstrated an ORR of 89.5%, while lung cancer (search) patients achieved an ORR of 88.9%.
Superior Brain Penetration and Resistance Profile
As a next-generation TRK (search) inhibitor, zurletrectinib exhibits strong brain penetration activity, achieving an intracranial objective response rate (IC-ORR) of 100% and a 12-month intracranial duration of response (IC-DOR) of 100%. This capability enables strong and durable control of brain lesions, addressing a critical need for patients with brain metastases (search).
"The unique structure of zurletrectinib allows it to cross the blood-brain barrier and maintain effective therapeutic concentrations in cerebrospinal fluid, providing new treatment options for patients with brain metastases (search)," said Qiming Wang, professor at the Henan Cancer Hospital.
The drug also demonstrates the ability to overcome acquired resistance to first-generation TRK (search) inhibitors, offering new hope for patients who have developed resistance to existing treatments. Its high selectivity significantly reduces off-target toxicity, ensuring good safety profiles for long-term medication without compromising quality of life.
Addressing Significant Unmet Medical Need
NTRK (search) fusion genes are present in various types of tumors and have been identified in over 26 solid tumors. In China, approximately 6,500 new cases of tumors carrying NTRK fusion genes occur annually. These patients often experience short survival periods, rapid disease progression, and high disability rates. Due to the low adoption rate of next-generation sequencing (NGS) as the current gold-standard detection method, diagnosis is often delayed, creating significant unmet clinical needs.
"NTRK (search) fusion-positive tumors often progress rapidly and have limited treatment options," noted Yizhuo Zhang, professor at the Sun Yat-Sen University Cancer Center. "Zurletrectinib has demonstrated remarkable efficacy, particularly in achieving an ORR of 100% in adolescent patients."
Convenient Dosing and Future Development
Zurletrectinib offers a convenient once-daily, two-tablet oral dosing regimen, bringing significant convenience to patients requiring long-term treatment. The drug has been included in the "SPARK Program" by China's NMPA, a pilot initiative to encourage the development of pediatric anti-tumor drugs. InnoCare anticipates submitting a new drug application (NDA) for zurletrectinib to treat pediatric patients aged 2 to 12 in the near future.
"Zurletrectinib is of significant clinical importance for patients with NTRK fusion-positive solid tumors (search)," said Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare. "We believe that zurletrectinib will bring new hope to Chinese patients with solid tumors."
The approval represents a significant milestone for InnoCare and provides a new therapeutic option for patients with NTRK fusion-positive solid tumors (search) who previously had limited treatment alternatives.